In other studies performed with treatment models, in which the PPARγ agonists were administered after the establishment of significant fibrosis (a more clinically relevant model), the results were less favorable, as pioglitazone or rosiglitazone failed to reduce fibrosis in rodents subjected to CCl4 or cholestasis models of hepatic fibrosis [16,22]. The gene discussed is PPARG; the disease is Hepatic fibrosis.